GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

GSK3050002   Click here for help

GtoPdb Ligand ID: 9623

Synonyms: E6071 | KANAb071
Immunopharmacology Ligand
Compound class: Antibody
Comment: GSK3050002 is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. This biologic is being developed by GlaxoSmithKline in collaboration with Morphotek, based on a non-humanized antibody originally identified by KAN Research Institute, Inc., a subsidiary of Eisai Co., Ltd.
No information available.
Summary of Clinical Use Click here for help
Phase 1 clinical study in healthy subjects (NCT01984047) revealed no major safety concerns, and provided proof-of-concept for this mechanism of preventing recruitment of CCR6+ cells to inflammatory sites [1]. A Phase 1 study in psoriatic arthritis (NCT02671188) is registered with ClinicalTrials.gov, but is not yet recruiting patients.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
GSK3050002 down-modulates the CCL20/CCR6 interaction and inhibits recruitment of CCR6+ cells to inflammatory sites [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01984047 Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 Phase 1 Interventional GlaxoSmithKline
NCT02671188 A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis Phase 1 Interventional GlaxoSmithKline